Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSND-201 in PTSD (Open-Label Extension)
NCT07670702Phase 3Enrolling by invitation
- Sponsor
- Transcend Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of TSND-201 in post-traumatic stress disorder (PTSD), sponsored by Transcend Therapeutics. Started Jun 2026; status: enrolling by invitation.
02
Drugs
TSND-201
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07670702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670702.